Gene Therapy Achieves 95% Success Rate in Treating Children with Rare Immune Disorder ADA-SCID
核心洞察
Experimental gene therapy restored immune function in 59 of 62 children with ADA-SCID (搜索), achieving 100% overall survival and 95% event-free survival over a mean follow-up of 7.5 years.
The lentiviral vector-based treatment showed superior safety compared to previous gamma-retroviral approaches, with no cases of leukemia (搜索) or serious genotoxic complications reported.
Cryopreserved stem cells demonstrated equivalent efficacy to fresh preparations, enabling centralized manufacturing and broader accessibility for patients worldwide.
An experimental gene therapy has demonstrated remarkable long-term success in treating children with ADA-SCID (搜索), a rare and deadly genetic immune disorder, according to results published in the New England Journal of Medicine. The treatment, developed by researchers at UCLA, University College London, and Great Ormond Street Hospital (搜索), achieved immune system restoration in 59 of 62 children, representing a 95% success rate with sustained benefits over more than seven years of follow-up.
Breakthrough Results in Rare Disease Treatment
Severe combined immunodeficiency (搜索) due to adenosine deaminase deficiency (搜索) (ADA-SCID (搜索)) affects children born with mutations in the ADA gene (搜索), which produces an enzyme essential for immune function. Without treatment, the condition is typically fatal within the first two years of life, as children face life-threatening infections from routine activities like attending school or playing with friends.
The study represents the largest and longest follow-up of a gene therapy of this kind to date, encompassing 474 total patient-years of follow-up data, including five patients who received therapy more than a decade ago. All 59 successfully treated patients maintained stable immune function beyond the initial recovery period, with no treatment-limiting complications reported.
"These results are what we hoped for when we first began developing this approach," said Dr. Donald Kohn, distinguished professor at UCLA and senior author of the study. "The durability of immune function, the consistency over time and the continued safety profile are all incredibly encouraging."
Superior Safety Profile Compared to Previous Approaches
The lentiviral vector-based gene therapy demonstrated significant safety advantages over earlier gamma-retroviral approaches. No cases of leukoproliferation, dominant clonality, or leukemia (搜索) were observed, addressing major concerns that plagued first-generation gene therapies. The treatment showed polyclonal integration patterns maintained up to 120 months, indicating stable and safe genetic modification.
Most adverse events were mild or moderate and related to routine preparatory procedures rather than the gene therapy itself. The three patients who did not respond successfully were able to return to standard-of-care therapies, with two receiving bone marrow transplants and one continuing enzyme replacement therapy.
Revolutionary Treatment Approach
The gene therapy process involves collecting a child's blood stem cells and using a modified lentivirus to deliver a healthy copy of the ADA gene (搜索). Once reinfused, the corrected stem cells begin producing healthy immune cells capable of fighting infections. While immune cell development starts shortly after reinfusion, it takes six to 12 months for the immune system to reconstitute to normal levels.
The treatment achieved 100% overall survival and demonstrated excellent immune reconstitution, with 98% of patients achieving immunoglobulin independence and good vaccine responses. Patients were able to discontinue anti-infective prophylaxis, allowing them to live normal lives without the severe isolation previously required.
Enhanced Accessibility Through Cryopreservation
A significant breakthrough in the study was the successful use of cryopreserved stem cells, which showed equivalent outcomes to fresh preparations. More than half of the treated children received frozen stem cell preparations, demonstrating that the therapy can be manufactured centrally and shipped to treatment centers worldwide.
"The freezing approach allows children with ADA-SCID (搜索) to have their stem cells collected locally, then processed at a manufacturing facility elsewhere and shipped back to a hospital near them," explained Dr. Katelyn Masiuk, former clinical project lead in the Kohn lab and co-first author. "This removes the need for patients and their families to travel long distances to specialist centers."
Path to Regulatory Approval
With support from the California Institute for Regenerative Medicine (搜索), the UCLA team is working to complete steps necessary for FDA approval. Rarity PBC (搜索) has licensed the gene therapy from UCLA Technology Development Group and is partnering with commercial manufacturing organizations to produce the therapy under pharmaceutical-grade conditions.
"Our goal is to have this therapy FDA-approved within two to three years," Kohn stated. "The clinical data strongly supports approval — now we need to demonstrate that we can manufacture the treatment under commercial pharmaceutical standards."
Patient Success Story: A Decade of Normal Life
The transformative impact of the therapy is exemplified by Eliana Nachem, now 11 years old, who received treatment at 10 months old in 2014. After living in complete medical isolation for her first months of life, with HEPA air filters running constantly and all food and toys sterilized, Eliana now attends public school, plays basketball, and lives an unrestricted childhood.
"Now the biggest thing I have to worry about is her entering middle school and bossing me around," said her mother Caroline with a laugh. "I am eternally grateful to every single scientist, doctor, lab worker, nurse, hospital security guard — all the people who had anything to do with this gene therapy coming into existence and saving her."
Clinical Implications and Future Outlook
The study consolidates lentiviral gene therapy as a priority and safe curative option for ADA-SCID (搜索), with direct implications for treatment guidelines. The therapy offers significant advantages over current standard treatments, including bone marrow transplantation and weekly enzyme injections, which carry limitations and potential long-term risks.
The treatment requires only a single infusion in most cases and uses the patient's own cells, avoiding complications associated with allogeneic transplantation such as graft-versus-host disease. Additionally, if gene therapy should fail, patients remain candidates for allogeneic transplant, whereas prior transplantation precludes access to gene therapy.
The research was funded by the National Institutes of Health, the U.S. Department of Health & Human Services, the California Institute for Regenerative Medicine (搜索), Orchard Therapeutics (搜索), and the U.K. National Institute for Health and Care Research Great Ormond Street Hospital (搜索) Biomedical Research Centre.